» Articles » PMID: 38672011

The Effect of Antipsychotics on Cognition in Schizophrenia-A Current Narrative Review

Overview
Journal Brain Sci
Publisher MDPI
Date 2024 Apr 27
PMID 38672011
Authors
Affiliations
Soon will be listed here.
Abstract

The majority of schizophrenia-affected individuals display deficiencies in multiple cognitive domains such as attention, working memory, long-term memory, and learning, deficiencies that are stable throughout the disease. The purpose of this narrative review was to examine the effect of antipsychotics on several cognitive domains affected by schizophrenia. We searched MEDLINE, Elsevier, Scopus, and DOAJ databases for randomized controlled trials and other studies investigating the effects of typical and atypical antipsychotics on cognition in patients with schizophrenia in studies conducted in the last decade. The majority of studies included in this review showed that antipsychotics (especially SGAs) have positive effects on both cognition and general psychopathology of schizophrenia. We mention that treatment with antipsychotic substances represents an ongoing effort of the researchers, who are constantly searching for the best approach to meet the mental health needs of schizophrenia patients. Even with those positive results, it should be noted that more studies are needed in order to fully observe the various effects of certain antipsychotic substances on cognition.

Citing Articles

D3 Receptor-Targeted Cariprazine: Insights from Lab to Bedside.

Barabassy A, Dombi Z, Nemeth G Int J Mol Sci. 2024; 25(11).

PMID: 38891871 PMC: 11172134. DOI: 10.3390/ijms25115682.

References
1.
Zuardi A, Morais S, Guimaraes F, Mechoulam R . Antipsychotic effect of cannabidiol. J Clin Psychiatry. 1995; 56(10):485-6. View

2.
Potkin S, Kunovac J, Silverman B, Simmons A, Jiang Y, DiPetrillo L . Efficacy and Safety of a Combination of Olanzapine and Samidorphan in Adult Patients With an Acute Exacerbation of Schizophrenia: Outcomes From the Randomized, Phase 3 ENLIGHTEN-1 Study. J Clin Psychiatry. 2020; 81(2). DOI: 10.4088/JCP.19m12769. View

3.
Meltzer H, Rabinowitz J, Lee M, Cola P, Ranjan R, Findling R . Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance. Am J Psychiatry. 1997; 154(4):475-82. DOI: 10.1176/ajp.154.4.475. View

4.
Hori H, Noguchi H, Hashimoto R, Nakabayashi T, Omori M, Takahashi S . Antipsychotic medication and cognitive function in schizophrenia. Schizophr Res. 2006; 86(1-3):138-46. DOI: 10.1016/j.schres.2006.05.004. View

5.
Woodward N, Purdon S, Meltzer H, Zald D . A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol. 2005; 8(3):457-72. DOI: 10.1017/S146114570500516X. View